Cargando…

New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression

Schizophrenia and depression are heterogeneous disorders. The complex pathomechanism of the diseases imply that medication responses vary across patients. Many psychotropic drugs are available but achieving optimal therapeutic effect can be challenging. The evidence correlates well with clinical obs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Orzelska-Górka, Jolanta, Mikulska, Joanna, Wiszniewska, Anna, Biała, Grażyna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500595/ https://www.ncbi.nlm.nih.gov/pubmed/36142523 http://dx.doi.org/10.3390/ijms231810624

Ejemplares similares

The Importance of l-Arginine:NO:cGMP Pathway in Tolerance to Flunitrazepam in Mice
por: Talarek, Sylwia, et al.
Publicado: (2016)

New atypical antipsychotics for schizophrenia: iloperidone
por: Caccia, Silvio, et al.
Publicado: (2010)

Atypical antipsychotics in the treatment of early-onset schizophrenia
por: Hrdlicka, Michal, et al.
Publicado: (2015)

Research in the Field of Drug Design and Development
por: Biala, Grazyna, et al.
Publicado: (2023)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
por: Faries, Douglas, et al.
Publicado: (2005)

Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome
por: Jeon, Sang Won, et al.
Publicado: (2017)

The Mechanisms Involved in Morphine Addiction: An Overview
por: Listos, Joanna, et al.
Publicado: (2019)

NMDA Receptors and NO:cGMP Signaling Pathway Mediate the Diazepam-Induced Sensitization to Withdrawal Signs in Mice
por: Talarek, Sylwia, et al.
Publicado: (2017)

Atypical Antipsychotics in the Treatment of Depressive and Psychotic Symptoms in Patients with Chronic Schizophrenia: A Naturalistic Study
por: Innamorati, Marco, et al.
Publicado: (2013)

HPA Axis in the Pathomechanism of Depression and Schizophrenia: New Therapeutic Strategies Based on Its Participation
por: Mikulska, Joanna, et al.
Publicado: (2021)

Atypical antipsychotics as add-on treatment in late-life depression
por: Cakir, Sibel, et al.
Publicado: (2016)

Schizophrenia, Depressive Symptoms, and Antipsychotic Drug Treatment
por: Reynolds, Gavin P, et al.
Publicado: (2021)

Atypical Antipsychotics and Other Therapeutic Options for Treatment of Resistant Major Depressive Disorder
por: Seo, Rubo J., et al.
Publicado: (2010)

Minimizing Cardiovascular Adverse Effects of Atypical Antipsychotic Drugs in Patients with Schizophrenia
por: Khasawneh, Fadi T., et al.
Publicado: (2014)

Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2006)

Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2008)

Patterns of Adherence to Oral Atypical Antipsychotics Among Patients Diagnosed with Schizophrenia
por: MacEwan, Joanna P., et al.
Publicado: (2016)

Severity in schizophrenia patients receiving atypical antipsychotic medications
por: Alam Fatmi1j, Syed Meraj, et al.
Publicado: (2022)

Asenapine: an atypical antipsychotic with atypical formulations
por: Musselman, Meghan, et al.
Publicado: (2021)

Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US
por: O’Day, Ken, et al.
Publicado: (2013)

Early predictors of poor treatment response in patients with schizophrenia treated with atypical antipsychotics
por: Chen, Yi-Lung, et al.
Publicado: (2018)

Atypical antipsychotics, dystonia, and psychotic depression: old solutions for new problems
por: Gazzellone, Matthew J., et al.
Publicado: (2022)

Osteoporosis Associated with Antipsychotic Treatment in Schizophrenia
por: Wu, Haishan, et al.
Publicado: (2013)

Treatment Responses of Cognitive Function and Plasma Asymmetric Dimethylarginine to Atypical Antipsychotic in Patients With Schizophrenia
por: Yu, Zhi-min, et al.
Publicado: (2019)

Costs in the Treatment of Schizophrenia in Adults Receiving Atypical Antipsychotics: An 11-Year Cohort in Brazil
por: Barbosa, Wallace Breno, et al.
Publicado: (2018)

Call to Caution with the Use of Atypical Antipsychotics for Treatment of Depression in Older Adults
por: Amodeo, Katherine, et al.
Publicado: (2016)

Amantadine in the Treatment of Sexual Inactivity in Schizophrenia Patients Taking Atypical Antipsychotics—The Pilot Case Series Study
por: Krzystanek, Marek, et al.
Publicado: (2021)

Association of Typical versus Atypical Antipsychotics with Symptoms and Quality of Life in Schizophrenia
por: Fujimaki, Koichiro, et al.
Publicado: (2012)

Neural Basis for the Ability of Atypical Antipsychotic Drugs to Improve Cognition in Schizophrenia
por: Sumiyoshi, Tomiki, et al.
Publicado: (2013)

A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics
por: Gilca, Marilena, et al.
Publicado: (2014)

PM441. Long term atypical antipsychotic treatment improves cognitive performance in schizophrenia but not surpassing conventional antipsychotic drugs effects.
por: Vera, Gabriel Selva, et al.
Publicado: (2016)

Anti-stress Properties of Atypical Antipsychotics
por: Sanson, Alice, et al.
Publicado: (2020)

Characteristics of Seltorexant—Innovative Agent Targeting Orexin System for the Treatment of Depression and Anxiety
por: Ziemichód, Wojciech, et al.
Publicado: (2023)

Antipsychotic Polypharmacy in Treatment of Schizophrenia; Should or Should Not?
por: Pae, Chi-Un
Publicado: (2020)

Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression
por: Loebel, Antony, et al.
Publicado: (2015)

Influence of an inconsistent appearance of antipsychotics on drug adherence in patients with schizophrenia
por: Lertxundi, Unax, et al.
Publicado: (2018)

Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics
por: Lally, John, et al.
Publicado: (2016)

Forms of antipsychotic therapy: improved individual outcomes under personalised treatment of schizophrenia focused on depression
por: Babinkostova, Zoja, et al.
Publicado: (2011)

Asenapine, a new sublingual atypical antipsychotic
por: Balaraman, R, et al.
Publicado: (2010)

Effects of zinc sulfate on schizophrenia symptoms in patients undergoing atypical antipsychotic pharmacotherapy
por: Behrouzian, Forouzan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_09r1kbe7gb7vo1ef17ti2r2eh4